Bioregulators · Dosing reference

Livagen dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyCPreclinical researchNone established

Full research page Cycle-length evidence Compare Prefer Amiravo on Google

Regulatory status: Not approved — research use only
Human amounts: None established in humans
Route studied: —
Frequency: Not established
Half-life: Not established
Evidence grade: Grade C · Preclinical research
Vial sizes on the market: 20 mg
Other forms seen: —

What Livagen is

Livagen is a short synthetic bioregulator peptide, investigated in cell research on chromatin state and tissue-specific gene expression.

The mechanism proposed for this peptide is epigenetic rather than receptor-mediated. Across several studies in lymphocytes cultured from donors aged 75–91, Livagen was reported to activate ribosomal genes in the nucleolar organiser regions of acrocentric chromosomes, to decondense densely packed chromatin, and to release genes the authors describe as repressed by age-related condensation of euchromatic regions [3,… How it works →

Key evidence

Khavinson et al., Bulletin of Experimental Biology and Medicine · 2002 · Cells (lymphocytes cultured from elderly human donors)
Livagen was reported to activate ribosomal genes, decondense pericentromeric structural heterochromatin and release genes the authors describe as repressed by age-related condensation of euchromatic regions. ³
Lezhava and Jokhadze, Annals of the New York Academy of Sciences · 2007 · Cells (lymphocytes cultured from donors aged 80–91 and from controls aged 18–30)
Cobalt chloride increased chromosomal aberrations in cells from old donors; Livagen was associated with a lower aberration frequency (3.4 ± 0.6% versus 4.2 ± 0.7% in the control group) and with a shift of sister chromatid exchanges towards telomeric heterochromatin (12.0 ± 1.2% versus 2.8 ± 0.5% in controls). ⁵
Dzhokhadze et al., Georgian Medical News (in Russian) · 2014 · Cells (lymphocyte cultures from patients with atherosclerosis aged 80 and older, and younger controls)
Patients with atherosclerosis showed higher genomic instability on all measured parameters irrespective of age; Livagen alone and combined with cobalt ions was reported to move those indices towards control values. The authors' conclusion that this proves efficacy in preventing atherosclerosis is not supported by a cell-culture design. ⁶

All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered Livagen. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

No human study durations are recorded for Livagen.

Cycle-length evidence for Livagen

Livagen draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

sizes on the market

2 · Water added

3 · Amount per draw

4 · Syringe

Your mix

20 mg + 2 mL water = 10 mg/mL

10 units holds 1 mg

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	40	—
1 mL	20	—
1.5 mL	13.33	—
2 mL	10	—
2.5 mL	8	—
3 mL	6.667	—
5 mL	4	—

Supplies and handling

Lyophilized vial
Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
Sterile diluent
The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
Graduated syringes
Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
Alcohol prep pads
For wiping vial stoppers before each puncture.
Nitrile gloves
Clean gloves for aseptic handling.
Sharps container
Puncture-resistant container for used needles.

Step-by-step reconstitution guide Storage and transport accessories

Storage

Handling should follow the certificate of analysis and written documentation supplied with the specific lot; no stability or handling data specific to this compound were identified in the sources reviewed. Short lyophilised peptides are generally treated as hygroscopic, light-sensitive solids whose reconstituted solutions are chemically less stable than the dry material. Amiravo does not provide preparation, reconstitution or administration instructions.

Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent: The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed: Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles: Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution: This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed: Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status: Not approved by the FDA for any use; no human drug labeling matching this name was returned by the openFDA Drug Label API ^13.
United States (FDA): There is no approved FDA application for this peptide; an openFDA Drug Label API query returned no matching human drug labeling ^13. Neither "livagen" nor "Lys-Glu-Asp-Ala" appears in any of the three categories of FDA's list of bulk drug substances nominated for use in compounding under section 503A of the FD&C Act, as updated 14 May 2026 ^14.
Sport (WADA): Not named in the WADA 2026 Prohibited List ^15. That absence is hedged negative evidence and not a clearance. Section S0 prohibits at all times "any pharmacological substance which is not currently approved by any governmental regulatory health authority for human therapeutic use" and states that the class "covers many different substances including but not limited to" its named examples; section S2 prohibits the listed substances "and other substances with similar chemical structure or similar biological effect(s)" ^15.

Status varies by country and changes over time. How we describe regulatory status.

Livagen compared with related compounds

Compound	Status	Evidence	Human amounts	Half-life
Livagen	Not approved — research use only	C	None established	—
Vesugen	Not approved — research use only	C	None established	—
Cortagen	Not approved — research use only	C	None established	—
Pinealon	Not approved — research use only	C	None established	—
Thymalin	Not approved — research use only	B	None established	—
Testagen	Not approved — research use only	D	None established	—

Frequently asked questions

What doses of Livagen have been studied in humans?

None that establish an amount. Livagen is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.

Is there an established Livagen cycle length?

No. We found no human studies that report treatment duration for Livagen.

How much bacteriostatic water should be added to a Livagen vial?

There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.

How many units is a given amount on an insulin syringe?

On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.

Is Livagen FDA-approved?

Not approved — research use only. Not approved by the FDA for any use; no human drug labeling matching this name was returned by the openFDA Drug Label API ^13.

References

Livagen [Supplementary Concept] — entry terms lysyl-glutamyl-aspartylalanine, Lys-Glu-Asp-Ala Medical Subject Headings, U.S. National Library of Medicine. 2026
Livagen (CID 87919683) — compound record, C18H31N5O9, 461.5 g/mol, CAS 433257-50-2 PubChem, U.S. National Library of Medicine. 2026
Effects of Livagen peptide on chromatin activation in lymphocytes from old people Bulletin of Experimental Biology and Medicine. 2002
Effects of short peptides on lymphocyte chromatin in senile subjects Bulletin of Experimental Biology and Medicine. 2004
Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals Annals of the New York Academy of Sciences. 2007
Genomic instability in atherosclerosis (in Russian) Georgian Medical News. 2014
Epigenetic modification under the influence of peptide bioregulators on the “old” chromatin Georgian Medical News. 2023
Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages (in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2005
Tissue-specific effects of peptides Bulletin of Experimental Biology and Medicine. 2001
The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology (review, in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2020
Evaluation of genomic parameters in ductal breast cancer patients and the ability of its correction (in Russian) Georgian Medical News. 2017
ClinicalTrials.gov registry query for "livagen" (0 studies returned) ClinicalTrials.gov (U.S. National Library of Medicine). 2026
openFDA Drug Label API query for "livagen" (no approved human drug labeling for a peptide of this name) U.S. Food and Drug Administration / openFDA. 2026
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) U.S. Food and Drug Administration. 2026
World Anti-Doping Code International Standard — Prohibited List 2026 (effective 1 January 2026) World Anti-Doping Agency. 2026
PubMed query for "livagen" (19 records) PubMed / NCBI Entrez (U.S. National Library of Medicine). 2026

Last reviewed October 23, 2026 by the Amiravo editorial team. Editorial policy · Report an error